FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17 ...Middle East

PR Newswire - News
FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg for use in the treatment of obesity in adolescents (12–17 years) with a body weight above 60 kg...

Hence then, the article about fda approves saxenda for the treatment of obesity in adolescents aged 12 17 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17 )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News